A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol
Part of paid clinical trials in Knoxville, Tennessee.
- Sponsor
- Sanofi
- Study ID
- NCT02940379
- Phase
- PHASE1
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- sotagliflozin (SAR439954) — DRUGPharmaceutical form: tablet Route of administration: oral
- midazolam — DRUGPharmaceutical form: HCl syrup Route of administration: oral
- metoprolol — DRUGPharmaceutical form: tablet Route of administration: oral
Study Details
Primary Objective: To assess the effect of repeated once-daily oral doses of sotagliflozin on CYP2D6 and CYP3A activities using a CYP probe cocktail of metoprolol and midazolam. Secondary Objective: To assess the clinical and laboratory safety of sotagliflozin coadministered with the cocktail probes as compared to that of cocktail probes alone.
Key Dates
- Start date
- Oct 31, 2016
- Status verified
- Apr 2022
- Primary completion
- Dec 31, 2016
- Completion
- Dec 31, 2016
Study Design
- Enrollment
- 24 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort 1Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 1 of Sotagliflozin plus cocktail) after 3 days
- Experimental: Cohort 2Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 2 of Sotagliflozin plus cocktail) after 3 days
Primary Outcome Measure
Assessment of midazolam pharmacokinetic (PK) parameter: Area under the curve (AUC) [ Time Frame: Day 1 to Day 2 of Treatment A Period ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Investigational Site Number 840001 | Knoxville | Tennessee | 37920 | - |
Find similar trials in Knoxville, TN
By condition
By specialty
By research site
Related Studies
- Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseasePHASE3 · Recruiting · Prokidney · Huntsville, Alabama
- GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With DiabetesRecruiting · Medtronic MiniMed, Inc. · Little Rock, Arkansas
- Evaluation of the Fully Closed Loop Omnipod® System in Type 2 DiabetesRecruiting · Insulet Corporation · Santa Barbara, California
- Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)Recruiting · Petter Bjornstad · Aurora, Colorado